Sat.Apr 16, 2022 - Fri.Apr 22, 2022

article thumbnail

GSK goes for gold as FDA starts review of daprodustat

pharmaphorum

GlaxoSmithKline says the FDA has started its review of daprodustat for anaemia associated with chronic kidney disease (CKD), as it strives to succeed where two other rivals in the HIF-PHI class have failed. GSK has submitted daprodustat base on its ASCEND phase 3 programme, which included five trials across both dialysis and non-dialysis patients and showed that the drug offered an oral alternative to injectable erythropoietin stimulating agents (ESAs) for anaemia, without sacrificing efficacy.

122
122
article thumbnail

DNA analysis uncovers new cancer treatment clues

Pharma Times

Researchers were able to detect specific combinations of genetic alterations which may hold key to the growth of cancers

130
130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Clinical trial evolution, innovation center of Oracle Health Sciences event

Outsourcing Pharma

The two-day Oracle Health Sciences Connect will gather an array of research experts to discuss how to make the most of emerging technologies and practices.

118
118
article thumbnail

Which pharmaceutical companies have the most syrup dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most syrup dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most syrup dosed drugs…. The post Which pharmaceutical companies have the most syrup dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

US study finds high rates of unneeded antibiotic prescribing

pharmaphorum

A study has found that there is still a very high level of inappropriate antibiotic prescribing to patients in the US, particularly to older and Black patients. Sifting through data from around seven billion outpatient visits to doctor’s offices, hospital clinics and emergency departments over a seven-year period, the researchers found that almost three-quarters (74%) of antibiotics prescribed to patients aged 65 years or older, and two thirds (64%) to Black patients, were unnecessary.

Hospitals 122
article thumbnail

New study reveals emotional and psychological impact of infertility

Pharma Times

Infertility is estimated to affect one in seven couples across the UK and can have a profound effect on mental health

128
128

More Trending

article thumbnail

Five Takeaways from the Big Three PBMs’ 2022 Formulary Exclusions (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: PBM Industry Update: Trends, Controversies, and Outlook. Click here to see the original post and comments from January 2022. For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies.

article thumbnail

Ampio slumps as FDA delivers knee osteoarthritis shock

pharmaphorum

Ampio Pharma’s candidate therapy for knee osteoarthritis has been knocked back by the FDA, which will likely now require a new clinical trial of the drug before it will consider a review. Shares in the US biotech have fallen sharply after it revealed that the regulator did not accept changes to a phase 3 trial of the drug – called Ampion – that the company put forward in order to make it serve as a confirmatory pivotal study.

Immunity 110
article thumbnail

NICE releases revised guidelines on antidepressants

Pharma Times

The new guidelines focus on key areas of prescription, management of withdrawal and severity of withdrawal symptoms

article thumbnail

Tech Innovations: April 2022

Outsourcing Pharma

The latest news on expansions, innovations, awards, and more includes items from Eversana, DHL Supply Chain, X-Chem, Medidata, and other notable companies.

84
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Four Reasons Why PBMs Gain As Maximizers Overtake Copay Accumulators (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: PBM Industry Update: Trends, Controversies, and Outlook. Click here to see the original post and comments from February 2022. More than four years ago, I warned about the emerging trend of copay accumulators and outlined the costly consequences for patients. The latest data reveal that copay accumulator adjustment programs are now in the word list for a growing share of pharmacy benefit designs.

80
article thumbnail

FDA starts speedy review of Enhertu in lung cancer

pharmaphorum

AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if it will approve their HER2 drug Enhertu for non-small cell lung cancer (NSCLC) and add to its current uses in breast and gastric cancer. The US regulator has kicked off a priority review of Enhertu (trastuzumab deruxtecan) as a treatment for NSCLC with HER2 mutations after prior systemic therapy, setting up a decision in the third quarter of this year.

article thumbnail

New coalition formed to raise awareness of sight loss

Pharma Times

‘The Eyes Have It’ partnership will highlight the importance of eye health

138
138
article thumbnail

Covid Drugs Save Lives, but Americans Can’t Get Them

NY Times

Once again, a dysfunctional health care system has hindered our pandemic response.

article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Follow the Vial: The Buy-and-Bill System for Distributing and Reimbursing Provider-Administered Outpatient Drugs (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: PBM Industry Update: Trends, Controversies, and Outlook. Click here to see the original post and comments from October 2021. By reader request, we present below a channel flow chart illustrating the buy-and-bill process for provider-administered drugs. This chart complements Follow the Dollar: The U.S.

article thumbnail

Astellas takes $170m charge as it drops DMD gene therapies

pharmaphorum

Astellas has said it will book a $170 million impairment charge in its fourth quarter results as a result of a decision to halt the development of three gene therapy candidates for Duchenne muscular dystrophy in preclinical development. The write-down comes in the wake of problems affecting the Japanese drugmaker’s AT132 gene therapy candidate for rare disease X-linked myotubular myopathy (XLMTM), which was placed on clinical hold by the FDA last year after four patient deaths liked to pos

Labelling 105
article thumbnail

Oncomatryx announces 15m euros funding to conduct clinical trials

Pharma Times

Company at the forefront of developing personalised treatments against invasive cancer has raised 15m euros to conduct clinical trials

105
105
article thumbnail

Pharmaceutical companies with the most ‘New Patient Population’ drugs

Drug Patent Watch

This chart shows the companies which have received the most New Patient Population exclusivities in the past five years. New Patient Populations are one of the categories for which the…. The post Pharmaceutical companies with the most ‘New Patient Population’ drugs appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Ohio Doctor Is Acquitted of Killing Patients With Fentanyl

NY Times

The doctor, William Husel, had faced 14 counts of murder after his patients overdosed on fentanyl, the powerful opioid.

article thumbnail

The largest pharma company in Europe calls for interoperability

pharmaphorum

Ehab Youssef, area head of Europe North at Roche Pharmaceuticals, tells us why European countries need interoperability to ensure a more effective overall European healthcare system. COVID spotlighted the vulnerability of the healthcare system and the need for structural and technological change to help manage such as crisis. Though some regions have started to make the necessary changes, Youssef says Europe is lagging. “In general, there is a good progression in almost every country.

Diabetes 109
article thumbnail

King’s College London explore COVID-19 technology as heart attack cure

Pharma Times

Protein technology could dramatically improve prospects of heart attack victims by proliferating organ cells

117
117
article thumbnail

Why PBMs and Payers Are Embracing Insulin Biosimilars with Higher Prices—And What That Means for Humira (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: PBM Industry Update: Trends, Controversies, and Outlook. Click here to see the original post and comments from November 2021. An ironic postcript: Less than two months after my article was published, Cigna CEO David Cordani bragged about the cost savings from "aggressive adoption" of biosimilars.

article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Break Through Cancer announces $50m to power research collaboration

Outsourcing Pharma

The one-year-old organization is giving $50m USD in grants to encourage scientists from five cancer research centers to work together on cancer solutions.

59
article thumbnail

Digital therapy for osteoarthritis tops other methods, says study

pharmaphorum

A meta-analysis of published studies looking at web- app- or telehealth-based therapy for osteoarthritis has concluded that they outperform standard approaches to care. The study – published in the journal Osteoarthritis and Cartilage – focused on patients with osteoarthritis of the hip or knee, and compared the digitally-delivered exercises to standard approaches such as in-person physiotherapy, other forms of care, waitlisting and patient education.

103
103
article thumbnail

Shionogi and NEC collaborate on hepatitis B vaccine

Pharma Times

High unmet need in the area of hepatitis B therapies will see companies share responsibilities to develop the vaccine

Vaccines 110
article thumbnail

Scientists Question Data Behind an Experimental Alzheimer’s Drug

NY Times

Studies linked to Cassava Sciences, once a stock market favorite, have been retracted or challenged by medical journals.

67
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Cryoport buys French biostorage and logistics specialist

Outsourcing Pharma

Cryoport Inc has acquired Cell&Co BioServices, continuing its EMEA expansion efforts.

85
article thumbnail

Sarepta DMD rival PepGen files $115m IPO

pharmaphorum

Just days after dosing its first patient in a Duchenne muscular dystrophy trial, US biotech PepGen has pushed the button on an initial public offering (IPO). The Boston-based company has filed with the US Securities and Exchange Commission to raise up to $115 million from the IPO, according to a Renaissance Capital report. The funding will be used to continue the clinical development of lead oligonucleotide PGN-EDO51 for DMD, as well as two other oligo drugs PGN-EDODM1 for myotonic dystrophy ty

103
103
article thumbnail

Leeds health chief issues warning about the risks of missing MMR vaccinations

Pharma Times

The civil servant drew attention to vaccinations falling to lowest level in a decade

article thumbnail

Save America’s Patent System

NY Times

It needs to promote innovation, not reward legal trickery.

91
article thumbnail

New patent for Purdue Pharma drug OXYCONTIN

Drug Patent Watch

Annual Drug Patent Expirations for OXYCONTIN Oxycontin is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from eight suppliers. There are nineteen…. The post New patent for Purdue Pharma drug OXYCONTIN appeared first on DrugPatentWatch - Make Better Decisions.

52